Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Epidemiology of constipation in the US
3. Physician vs. patient's perception of constipation
4. Secondary causes of constipation
5. Primary causes of constipation
6. IBS-C vs. chronic constipation: symptoms
7. Pathophysiology of chronic constipation
8. The reasons for constipation
9. Evaluation of constipation
10. DRE protocol
11. Colon transit study
12. SmartPill: whole gut transit and motility
13. Management strategies for constipation
14. Traditional treatments for chronic constipation
15. PEG
16. Treatment satisfaction for chronic constipation
17. Effects of lubiprostone on bowel movements
18. Efficacy of linaclotide in chronic constipation
19. Prucalopride treatment - chronic constipation
20. Probiotics for treatment of constipation
21. What is dyssynergia?
22. Biofeedback on constipation (1)
23. Biofeedback on constipation (2)
24. Biofeedback effects on CSBM and dyssynergia
25. Long term outcome of biofeedback on CSBM
26. Conclusions
27. Pathophysiological-based treatment approach
28. Algorithm approach to constipation
29. Common defecation disorders
30. Solitary rectal ulcer syndrome (1)
31. Solitary rectal ulcer syndrome (2)
32. Solitary rectal ulcer syndrome (3)
33. Changes before and after biofeedback therapy
34. Other improvements due to biofeedback therapy
35. Changes in sigmoidoscopy
36. Rectocele
37. Management of rectocele
38. Take home message

Topics Covered

• Disorders of pelvic floor dysfunction such as constipation, solitary rectal ulcer syndrome and rectocle are very common and cause significant bowel symptoms and problems
• Common presentations, underlying mechanisms and diagnostic modalities
• Common approaches for treatment including biofeedback therapy

Links

Series:

• Gastroenterology and Hepatology

Categories:

• Clinical Practice
• Metabolism & Nutrition

Therapeutic Areas:

• Gastroenterology & Nephrology

Talk Citation

Publication History

• Published on January 5, 2011

Financial Disclosures

• Prof. Satish S. C. Rao has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.